Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or even know they're an option. It's called pre-exposure prophylaxis, or ...

Just a few decades ago, human immunodeficiency virus, also known as HIV, was a death sentence for those who contracted ...

Prism Health North Texas, a community health center, participated in clinical trials for Merck's new HIV treatment, Idvynso.

The FDA has approved Idvynso (doravirine/islatravir) for virologically suppressed adults with HIV-1 as a replacement for current treatment regimens.

Researchers found that certain immune cells, genes, and the drug metformin may help keep HIV dormant after treatment stops, ...

For the first time since HIV was identified, early human trials are starting to show what long‑imagined “drug‑free control” of the virus might look like in practice. Instead of chasing a total ...

Human immunodeficiency virus-1 (HIV) is one of the most challenging viruses for doctors to treat. Even with effective antiretroviral therapy, immune cells infected with HIV can hide and lie inactive ...

Coinfection of HIV and HCV leads to worse outcomes, necessitating effective HCV treatment in this population. Direct-acting antivirals show over 95% efficacy, yet HCV clearance rates in coinfected ...

Researchers at the Manchester Institute of Biotechnology (MIB) have used engineering biology—an emerging technology that uses ...